Retatrutide, new Triple Hormone Receptor Agonist, Improves Weight Loss up to 30%, Knee Osteoarthritis Pain, Sleep Apnea Versus Placebo
Retatrutide treatment results in substantial weight loss among patients with obesity, as well as reduced pain in patients with knee osteoarthritis and reduced apnea-hypopnea events in patients with obstructive sleep apnea, according to the TRIUMPH-1 study.1 Earlier phase 2 trials including patients with obesity have indicated that once-weekly subcutaneous retatrutide resulted in substantial weight reductions